CN104193804A - Specific binding peptide of duck tembusu virus envelope E protein and application thereof - Google Patents
Specific binding peptide of duck tembusu virus envelope E protein and application thereof Download PDFInfo
- Publication number
- CN104193804A CN104193804A CN201410361045.1A CN201410361045A CN104193804A CN 104193804 A CN104193804 A CN 104193804A CN 201410361045 A CN201410361045 A CN 201410361045A CN 104193804 A CN104193804 A CN 104193804A
- Authority
- CN
- China
- Prior art keywords
- tembusu virus
- specific binding
- protein
- duck tembusu
- duck
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a specific binding peptide of a duck tembusu virus envelope E protein and an application thereof, belonging to the technical field of molecular biology of animal viruses. The specific binding peptide of the duck tembusu virus envelope E protein is obtained by randomly screening phages from 12 peptide libraries and has the amino acid sequence as follows: THRSWQGNSWYM. By using the specific binding peptide, the propagation of a duck tembusu virus HN1 strain in duck embryo fibroblasts can be inhibited, the virus copy number of a duck tembusu virus in the duck embryo fibroblasts can be remarkably reduced at different concentrations, and meanwhile the virus titer of the duck tembusu virus in the duck embryo fibroblasts can be remarkably reduced; and the specific binding peptide has no remarkable influences to the propagation of the duck embryo fibroblasts. The specific binding peptide of the duck tembusu virus envelope E protein has a favorable application prospect in preparation of drugs or feed additives for resisting duck tembusu virus diseases, and can be used for preventing and treating duck tembusu virus diseases.
Description
Technical field
The present invention relates to a kind of duck tembusu virus cyst membrane E protein-specific binding peptide, also relate to the application of this specific binding peptides simultaneously, belong to animal virus technical field of molecular biology.
Background technology
In recent years, southern china has broken out a kind of new duck viral transmissible disease, mainly cause the duck degradation of laying eggs, this disease is propagated rapidly, coverage is wide, morbidity is in earlier stage for continuing high heat, there is a certain proportion of nervous symptoms in the morbidity later stage, shows as paralysis, rolling, astasia and ataxia etc., and some sick duck is even dead within a few days.Cut open the dead duck of inspection, majority presents spleen and the obvious enlargement of kidney, and egg duck shows as hemorrhagic ovaritis.First this disease in Jiangsu and Zhejiang Provinces one band outburst, spreads to the ground such as Fujian and Anhui subsequently, afterwards in Jiangxi, Shandong, Hunan, Henan, Hebei breaks out in succession.For this disease, there is not yet report abroad.Domestic researchist has carried out separation, morphological observation, physicochemical property mensuration, RT-PCR detection and sequential analysis to its cause of disease, has now determined that this disease pathogen is duck tembusu virus, therefore claim that this disease is duck tembusu virus disease.This disease sickness rate is high, propagation is rapid, and morbidity scope is extremely wide, and provisions duck industry causes heavy economic losses.
Duck tembusu virus (Duck tembusu virus, DTMUV) is a kind of novel flavivirus, belongs to the single strand plus RNA virus of flaviviridae non-segmented negative, its virus particle is spherical in shape, diameter 45～50nm, has cyst membrane and fine prominent, and virus is approximately made up of 10990 Nucleotide.This virus, to heat, fatsolvent and sodium deoxycholate sensitivity, just loses infection activity when pH<5 or pH>10, more than 50 DEG C heat 60min and be inactivated.DTMUV can fasten propagation at part passage cells such as duck embryo, chicken embryo, DEF and Vero, BHK, C6/36.Its viral genome is made up of non-coding region and a middle open reading frame of 5 ' end, 3 ' end, the non-coding region length of 5 ' end is 142nt, containing I type m7GpppNp cap sequence, 3 ' end non-coding head of district 618nt, there is no poly (A) tail, the polyprotein precursor that 3410 amino-acid residues of open reading frame coding form.Precursor protein is cut into 3 kinds of structural protein (C, prM and E) and 7 kinds of Nonstructural Proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5) under the effect of host signal peptase and virus serine protease.
E albumen is a kind of envelope protein, and 501 amino acid of encoding, exist high conservative region and region of variability in its aminoacid sequence.E albumen is positioned at ripe virion surface, viruses adsorption acceptor, with host cell membrane merge and virus assembly process in there is important effect, and contain plurality of antigens epi-position, these epi-positions and viral recognition of host cell-membrane receptor, adsorb and enter cell, pathogenic and the induce immune responses of virus etc. are closely related, in virus infection, play an important role.In addition, E albumen also has good immunogenicity and reactionogenicity, is the main protection antigen of host's anti-infectious immunity, is also the desirable target antigen that detects this special viral antibody.
Display technique of bacteriophage is the effective means of a Study on Protein molecular interaction of rising in recent years, there is quick, efficient, phenotype and the feature such as genotype is consistent, be widely used in recent years the research field such as screening of peptide medicament, inhibiting peptide, antigenic epitope.Utilize the polypeptide of display technique of bacteriophage screening duck tembusu virus cyst membrane E protein-specific combination, and study this polypeptide on DTMUV in the impact aspect DEF propagation, the control that can be DTMUV provides a new approach, has good application prospect.
Summary of the invention
The object of this invention is to provide a kind of duck tembusu virus cyst membrane E protein-specific binding peptide.
Meanwhile, the present invention also provides a kind of application of duck tembusu virus cyst membrane E protein-specific binding peptide.
In order to realize above object, the technical solution adopted in the present invention is:
Duck tembusu virus cyst membrane E protein-specific binding peptide, its aminoacid sequence is as shown in SEQ ID NO:1.
Described duck tembusu virus is duck tembusu virus HN1 strain.
The application of duck tembusu virus cyst membrane E protein-specific binding peptide, be specially the application of specific binding peptides in the anti-duck tembusu virus disease of preparation medicine or the fodder additives of (suppress duck tembusu virus propagation, breed at DEF as suppressed duck tembusu virus).
Beneficial effect of the present invention:
The present invention obtains DTMUV HN1 strain E albumen by gene engineering method, and using DTMUV HN1 strain E albumen as target, utilize phage random 12 peptide library selections to obtain duck tembusu virus cyst membrane E protein-specific binding peptide, its aminoacid sequence is: THRSWQGNSWYM.This specific binding peptides can suppress the propagation of duck tembusu virus HN1 strain at DEF.Standard mtt assay detects the impact of E protein-specific binding peptide on DEF propagation, result demonstration, and polypeptide itself has no significant effect the propagation of DEF.Quantitative fluorescent PCR and TCID50 detect E protein-specific binding peptide on duck tembusu virus in the impact aspect DEF propagation, result shows, this polypeptide all can significantly be lowered the viral copy number of duck tembusu virus in DEF under different concns (0.02 μ g/mL, 0.2 μ g/mL, 2 μ g/mL, 20 μ g/mL), significantly reduces the virus titer of duck tembusu virus in DEF simultaneously.Result shows, E protein-specific suppresses the propagation of duck tembusu virus at DEF in conjunction with Toplink, in the control of duck tembusu virus disease, has a good application prospect.
Brief description of the drawings
Fig. 1 is that in the embodiment of the present invention 1, recombinant expression plasmid pET32a-E builds schematic diagram;
Fig. 2 is that in the embodiment of the present invention 1, ELISA detects the combination activity of Phage Display Peptide to target molecule;
Fig. 3 is embodiment 1 pnagus medius positive colony competition inhibition test result;
Fig. 4 is the impact of DRMUV HN1 strain E protein-specific binding peptide on DEF propagation in test example;
Fig. 5 is specific binding peptides impact (Real time PCR) in DEF propagation on DRMUV HN1 strain in test example;
Fig. 6 is specific binding peptides impact (TCID50) in DEF propagation on DRMUV HN1 strain in test example.
Embodiment
Following embodiment is only described in further detail the present invention, but does not form any limitation of the invention.
Embodiment 1
The screening of duck tembusu virus cyst membrane E protein-specific binding peptide in the present embodiment, comprises the following steps:
1) ordinary method is prepared DTMUV HN1 strain cyst membrane E albumen
(1) structure of recombinant expression plasmid pET32a-E
The gene order (sequence number: JQ669731) of the DTMUV HN1 strain E albumen of delivering according to GenBank; utilize DNAStar software analysis; design a pair of Auele Specific Primer P1 and P2; primer two ends add respectively restriction enzyme site EcoR I and Xba I and protectiveness base (Takara company is synthetic), and underscore part is restriction enzyme site.
Upstream primer P1:5 '-CCG
gAATTCtTCAGCTGTCTGGGGATGCA-3 ' (as SEQ ID NO:2, underscore part is EcoR I restriction enzyme site);
Downstream primer P2:5 '-CGA
tCTAGAaTTGACATTTACTGCCAGG-3 ' (as SEQ ID NO:3, underscore part is Xba I restriction enzyme site).
Ordinary method is extracted DTMUV HN1 strain RNA, and (viral RNA extracts test kit, Nanjing Tiangen company limited), obtain the full length gene sequence (Invitrogen single stage method RT-PCR test kit) of E albumen by conventional reverse transcription PCR, the E protein gene cloning obtaining is entered in pMD18-T carrier, and check order.By the E protein gene object fragment on pMD18-T carrier after EcoR I and Xba I enzyme are cut, be cloned into pET32a carrier, build recombinant expression plasmid pET32a-E, and identify with EcoR I and Xba I double digestion and PCR, identify that positive plasmid is recombinant expression plasmid pET32a-E, serve extra large Invitrogen company's order-checking (seeing Fig. 1).
(2) abduction delivering of recombinant expression plasmid pET32a-E and purifying
Adopt CaCl
2conversion method, is transformed into recombinant plasmid pET32a-E in e. coli bl21 (DE3) competent cell, and screening positive clone is the positive gene engineering strain containing the gene of DTMUV HN1 strain E albumen.Positive gene engineering strain, in 37 DEG C of cultivations, is treated to A
600value reaches at 0.5 o'clock (0.4～0.6 all can), add IPTG to final concentration be 0.8mM, carry out abduction delivering.Collect the thalline that different induction times are expressed, ultrasonic disruption, centrifugally get respectively cleer and peaceful precipitation and carry out SDS-PAGE electrophoresis afterwards, and taking the anti-DTMUV-1 serum of duck as primary antibodie, the anti-duck IgG of rabbit of HRP mark two anti-carries out Western blot analysis to expression product, finally with the colour developing of DAB colouring reagents box.By centrifugal the bacterium liquid of abduction delivering and results precipitation, with washings (5mM imidazoles, 0.5M NaCl, 20mM Tris-HCl, pH7.9) after resuspended thalline, centrifugal after ultrasonic treatment, solubility expression supernatant is carried out to purifying by protein N i post affinity chromatography, specific operation process is with reference to the Hisbind purification kit of Novagen company specification sheets, and E albumen, after ni-sepharose purification, obtains DTMUV HN1 strain E albumen.
2) the affine screening in phage random 12 peptide storehouses
(1) the DTMUV HN1 strain E albumen of coated purifying
The E albumen that said gene engineering is expressed, taking TBS dilution as 10 μ g/mL, is got the E albumen coated elisa plate after dilution, 100 μ L/ holes, and in the wet box of placement, 4 DEG C are spent the night; Tipping next day coating buffer, adds the TBST washing 3 times (at every turn leaving standstill 3min) containing 0.05%Tween20, kowtows dryly, then adds each hole with the TBS containing 5% skim-milk by 100 μ L/ holes, puts 37 DEG C of sealing 2h in wet box; Tipping confining liquid, with containing the TBST solution washing of 0.05%Tween20 3 times, kowtows dryly, and the enzyme plate be coated with is sealed, stand-by in 4 DEG C of preservations.
(2) affine screening
Dilute original library (being purchased from U.S. New England Biolabs, NEB company) to 1 × 10 with TBST
11pfu/mL, the library liquid 100 μ L that get after dilution join in the enzyme plate hole that is coated with in advance E albumen, and in the wet box of placement, 4 DEG C are spent the night.Abandon liquid in hole next day, and with TBST clean 10 times, in micropore, add 100 μ L0.2M Glycine-HCl (pH2.2), in the gentle shake of room temperature 10min, elutriant sucks in another clean Eppendorf tube, adds 15 μ L1M Tris-HCl (pH9.1) to neutralize above-mentioned elutriant.Measure the titre of a small amount of (～1 μ L) eluate, residue eluate joins (thalline in logarithm in earlier stage) in 20mL ER2738 culture, 37 DEG C of violent wave and culture 4.5h.Culture is proceeded in centrifuge tube, 4 DEG C 12, the centrifugal 10min of 000rpm.Supernatant liquor proceeds in another centrifuge tube, more centrifugal.Get 80% supernatant and proceed in new pipe, add the PEG/NaCl of 1/6 volume, 4 DEG C of precipitations are spent the night.Next day, 4 DEG C 12, the centrifugal PEG precipitation of 000rpm 15min.Abandon supernatant, ofer short duration centrifugal, discard residual supernatant.Throw out is resuspended in 1mL TBS, and suspension proceeds in Eppendorf tube, and 4 DEG C of centrifugal 5min make residual cells precipitation.Supernatant proceeds to another fresh Eppendorf tube, with the PEG/NaCl redeposition of 1/6 volume.Hatch 30min (15～60min all can) on ice.4 DEG C of centrifugal 10min, abandon supernatant, ofer short duration centrifugal, inhale and abandon remaining supernatant with micropipet.Throw out is resuspended in 200 μ L TBS, 0.02%NaN
3in.Centrifugal 1min, precipitates the insolubles of any remnants.Supernatant proceeds in new centrifuge tube, is the phage eluate after first round amplification.According to the dull and stereotyped titre of measuring the rear eluate of amplification of LB/IPTG/Xgal for conventional M13 method.Phagocytosis body fluid after the first round is increased is taking TBS dilution as 1 × 10
11pfu/mL, getting 100 μ L joins in advance and in the enzyme plate hole of coated E albumen, to carry out second and take turns screening, 37 DEG C of incubation 2h, abandon liquid in hole, and with cleaning 10 times containing the TBST solution of 0.05%Tween20, the same amplification of rear phage and the mensuration of titre of screening, repeats above step and carries out third round screening.
In screening process, every phagocytosis scale of construction that drops into screening of taking turns is designated as to the phagocytosis scale of construction that Input, wash-out obtain and is designated as Output, analyze more every output/input ratio (Input/Output) situation of taking turns, reflect the enrichment degree of specific binding phage.Taking turns screening through 3 finds: the phage that elutriation obtains is more and more, and specificity is more and more stronger, and wherein third round phage titre is 2.3 × 10
6pfu/mL.Phage ratio for input and output improves (seeing the following form 1) by wheel, shows that the phage with specific binding effect shows good concentration effect.
The enrichment of screening to phage that table 1 three-wheel is affine
3) amplification of mono-clonal phage
ER2738 is inoculated in 20mL LB substratum, and 37 DEG C are cultured to slightly muddy.With suction nozzle random 10 clones of picking respectively from third round elutriation thing of sterilizing.Each phage clone joins in every pipe ER2738 nutrient solution, cultivates 4.5h for 37 DEG C.By above-mentioned culture in 4 DEG C 12, the centrifugal 10min of 000rpm, supernatant moves into new centrifuge tube, more centrifugal.Get 80% supernatant in new centrifuge tube, add the PEG/NaCl of 1/6 volume.4 DEG C of precipitations spend the night (at least 1h).4 DEG C 12,000rpm15min centrifugation, abandons supernatant, then carries out of short duration centrifugally, discards remaining supernatant.Precipitation is resuspended in 1mL TBS, and suspension is proceeded to Eppendorf tube, and 4 DEG C of centrifugal 5min remove the residual cell in precipitation.Supernatant proceeds to new Eppendorf tube, adds the PEG/NaCl redeposition of 1/6 volume.Act on 30min (15～60min all can) on ice.4 DEG C of centrifugal 10min, abandon supernatant, then carry out of short duration centrifugally, discard remaining supernatant.Precipitation is resuspended in 50 μ L TBS, and M13 method is carried out phage titre mensuration routinely.
4) ELISA detect phage display small peptide to target molecule combination activity
Whether be combined with E protein-specific in order to detect the phage clone that obtains of screening, from third round screening, survey 20 single phage clones of random choose in the agar plate of titre, do indirect ELISA with the coated elisa plate of E albumen and test.(be dissolved in 0.1M pH8.6NaHCO with the target molecule E albumen of 100 μ L10 μ g/mL
3in) coated elisa plate, and establish PBS contrast.4 DEG C of coated spending the night in the wet box of sealing.After 4 DEG C of sealing 1h of confining liquid, PBST washing, adds 100 μ L single clone's to be measured phage supernatant (to be diluted to: 10
11pfu/mL) be small peptide to be measured, room temperature reaction 1h.After PBST washing, add the anti-M13-HRP binding substances that is diluted to working concentration, room temperature reaction 1h.PBST fully washs, and adds tmb substrate chromophoric solution, room temperature 30min, after add the H of 50 μ L2M
2sO
4termination reaction, surveys A450 value.
Result shows that wherein 10 clones show stronger positive findings (seeing Fig. 2).Called after P1, P2, P3, P4, P5, P6, P7, P8, P9, P10 respectively.
5) competition inhibition test
By above-mentioned 10 clones, do competitive ELISA experiment, further to identify whether the Phage Display Peptide being screened is combined with E protein-specific.In wet box, coated target molecule E albumen sealing (method is the same), add 100 μ L different concns (2.5 μ g/mL, 5 μ g/mL, 10 μ g/mL, 15 μ g/mL, 20 μ g/mL) E albumen and above-mentioned mono-clonal phage (to be diluted to: 10
11pfu/mL) equal-volume mixes, room temperature effect 10min, and every hole 100 μ L, room temperature jog is hatched 1h.PBST washes 6 times, adds anti-M13-HRP antibody, and room temperature jog is hatched 1h, and PBST washes 6 times, adds tmb substrate colour developing, surveys A450 value.
The calculation formula of inhibiting rate is shown in following formula (1):
Inhibiting rate (%)=(do not suppress A450 value-inhibition after A450 value)/do not suppress A450 value × 100% (1)
Result shows, can block the combination (seeing Fig. 3) of phage clone P3, P8 and coated E albumen with being combined in advance of E albumen.Illustrate that 12 peptides that insert in phage P3, P8 are the specific binding peptides of E albumen.
6) preparation of single stranded phage DNA
Dilute ER2738 overnight culture and be inoculated in LB substratum by 1:100, dividing and install in culture tube, every pipe 1mL.Choose a blue plaque (selecting less than the flat board of 100 plaques from total amount, to ensure that each plaque is only containing a DNA sequence dna) with sterilizing suction nozzle and add in above-mentioned 1mL culture tube the each clone that will identify pipe.37 DEG C of shaking tables are cultivated 5h (4.5～5h all can).Culture proceeds in Eppendorf tube, centrifugal 30s.Supernatant proceeds in new pipe, more centrifugal, then 500 μ L is proceeded in new centrifuge tube containing the supernatant of phage.Add 200 μ L PEG/NaCl, put upside down and mix, room temperature is placed 10min.Centrifugal 10min, abandons supernatant, ofer short duration centrifugal, and careful suction abandoned remaining supernatant.By 70% washing with alcohol precipitation, after being fully dried, precipitation is resuspended in 30 μ L TE (10mM Tris-HCl, pH8.0,1mM EDTA).
7) positive bacteriophage determined dna sequence
Extract after the single stranded DNA of the above-mentioned phage positive colony that is numbered P8, with-28gIII (as shown in SEQ ID NO:4) and-96gIII sequencing primer (as shown in SEQ ID NO:5) transfers to the order-checking of Shanghai Invitrongen company, to infer its corresponding aminoacid sequence, result demonstration, the aminoacid sequence of the DTMUV HN1 strain E protein-specific binding peptide obtaining is P8-12:THRSWQGNSWYM (as shown in SEQ ID NO.1).
8) chemically synthesized polypeptide
Adopt the synthetic aforementioned polypeptides P8-12 of solid-phase synthesis, by Shanghai section peptide, biological company limited is synthetic, and purity is more than 95%.
Embodiment 2
The application of duck tembusu virus cyst membrane E protein-specific binding peptide in the medicine of the anti-duck tembusu virus disease of preparation in the present embodiment, comprise the following steps: (duck tembusu virus cyst membrane E protein-specific binding peptide is synthesized by solid-phase polypeptide synthesis mode to get powder after the freeze-drying of duck tembusu virus cyst membrane E protein-specific binding peptide purifying, oppositely high performance liquid chromatography purifying, after purifying freeze-drying, purity reaches more than 95%), with the conventional supplementary product starch of field of medicaments, sucrose, talcum powder mixes, the tablet medicine of the duck tembusu virus that is inhibited propagation, duck tembusu virus cyst membrane E protein-specific binding peptide is as main antiviral activity composition in antiviral, every content of main ingredient is 0.1g, the percentage composition of main ingredient is 50%.Or polypeptide powder is dissolved with PBS damping fluid, be mixed with the polypeptide solution of different concns, for suppressing duck tembusu virus proliferation test.
Embodiment 3
The application of duck tembusu virus cyst membrane E protein-specific binding peptide in the fodder additives of preparation inhibition duck tembusu virus propagation in the present embodiment, comprise the following steps: by freeze-drying after duck tembusu virus cyst membrane E protein-specific binding peptide purifying, obtain purity and reach more than 95% polypeptide powder (purifying adopts high performance liquid chromatography, and freeze-drying adopts freeze-drying).Can add by feed weight 0.2～0.5 ‰ duck tembusu virus cyst membrane E protein-specific binding peptide, feed per ton adds 200～500 grams, polypeptide powder.
Test example
(1) impact of DTMUV HN1 strain E protein-specific binding peptide P8-12 on DEF propagation
To after the PBS rinsing 5 times for duck embryonic except brain, eye, four limbs, internal organ (4～5 times all can), cut into 1 mm
3(0.5～1.5mm
3all can) tissue block; To organize and move into culturing bottle, be inverted culturing bottle, be placed in 37 DEG C, 5%CO
2cultivate 4.5h (4～5h all can) in incubator; After tissue block is completely adherent, add nutrient solution 9ml (8～10mL all can), the superfine foetal calf serum of nutrient solution composition: DMEM+10% (FBS); Nutrient solution in reject culturing bottle, with after residue in PBS washing culturing bottle 2 times, with adding nutrient solution 9mL (8～10mL all can) to stop digestion after tryptic digestion; Postdigestive cell average mark packs in 2 culturing bottles, puts into 37 DEG C, 5%CO
2in incubator, continue to be cultured to 2 × 10
5cells/mL, is divided into 5 groups, and the 1st to the 4th group adds respectively the P8-12 peptide of different concns (0.02 μ g/mL, 0.2 μ g/mL, 2 μ g/mL, 20 μ g/mL).The 5th group for adding PBS blank group, continues to cultivate after 48h, adopts mtt assay to detect DEF propagation situation.
The calculation formula of cell proliferation rate is shown in following formula (2) relatively:
Cell proliferation rate=experimental group OD value/control group OD value × 100% (2) relatively
The calculation formula of cell inhibitory rate is shown in following formula (3):
Cell inhibitory rate=(control group OD value-experimental group OD value)/control group OD value × 100% (3)
Result shows, compared with PBS blank group, the relative proliferation rate of P8-12 peptide group cell under experimental concentration, all without noticeable change (P>0.05) (seeing Fig. 4), shows that DTMUV HN1 strain E protein-specific binding peptide P8-12 itself has no significant effect the propagation of DEF.
(2) DTMUV E protein-specific binding peptide P8-12 impact in DEF propagation on DTMUV HN1 strain
DEF is cultured to 2 × 10
5cells/mL, with the DMEM substratum flushing containing 1%FBS, adds serum-free DMEM substratum, then divides and is filled in 96 porocyte culture plates, and experiment is divided into 6 groups, and 1st～5 groups add the DTMUV virus liquid that virus infection plural number is 0.01MOI.The 6th group for adding PBS blank group, each group cell cultures 4h, discard infection liquid, PBS rinses cell 2 times, add the DMEM substratum containing 10%FBS, then in the 1st group to the 4th group, add respectively the P8-12 peptide of different concns (0.02 μ g/mL, 0.2 μ g/mL, 2 μ g/mL, 20 μ g/mL).Continue to cultivate after 48h, observed and recorded pathology, and calculate the TCID50 of each group by Reed and Munch formula, adopt fluorescence quantitative PCR method to detect DTMUV virus copy simultaneously.
Fluorescent quantitative PCR result shows, compared with the 5th group, the 1st group to the 4th group adds the polypeptide P8-12 (0.02 μ g/mL, 0.2 μ g/mL, 2 μ g/mL, 20 μ g/mL) of different concns all can significantly lower the viral copy number (see Fig. 5) of DTMUV HN1 strain in DEF, measure the DTMUV HN1 strain TCID50 of different experiments group, result also shows, the polypeptide P8-12 of different concns all can significantly reduce the virus titer (see Fig. 6) of DTMUV HN1 strain in DEF.Above result shows, DTMUV HN1 strain E protein-specific binding peptide P8-12 can suppress the propagation of DTMUV HN1 strain at DEF.
Claims (4)
1. duck tembusu virus cyst membrane E protein-specific binding peptide, is characterized in that: its aminoacid sequence is as shown in SEQ ID NO:1.
2. duck tembusu virus cyst membrane E protein-specific binding peptide according to claim 1, is characterized in that: described duck tembusu virus is duck tembusu virus HN1 strain.
3. an application for duck tembusu virus cyst membrane E protein-specific binding peptide as claimed in claim 1 or 2, is characterized in that: the application of described duck tembusu virus cyst membrane E protein-specific binding peptide in medicine or the fodder additives of the anti-duck tembusu virus disease of preparation.
4. the application of duck tembusu virus cyst membrane E protein-specific binding peptide according to claim 3, is characterized in that: described duck tembusu virus cyst membrane E protein-specific binding peptide suppresses the application of duck tembusu virus in medicine or the fodder additives of DEF propagation in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410361045.1A CN104193804B (en) | 2014-07-25 | 2014-07-25 | Duck tembusu virus cyst membrane E protein specific binding peptides and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410361045.1A CN104193804B (en) | 2014-07-25 | 2014-07-25 | Duck tembusu virus cyst membrane E protein specific binding peptides and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104193804A true CN104193804A (en) | 2014-12-10 |
| CN104193804B CN104193804B (en) | 2016-08-24 |
Family
ID=52079200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410361045.1A Expired - Fee Related CN104193804B (en) | 2014-07-25 | 2014-07-25 | Duck tembusu virus cyst membrane E protein specific binding peptides and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104193804B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109865138A (en) * | 2017-12-05 | 2019-06-11 | 江苏省农业科学院 | A kind of application of tembusu virus E protein receptor binding domains |
| CN114315991A (en) * | 2020-10-30 | 2022-04-12 | 广西壮族自治区动物疫病预防控制中心 | Competitive ELISA method based on duck flavivirus E protein and monoclonal antibody thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101412750A (en) * | 2008-10-08 | 2009-04-22 | 南京农业大学 | Bursin specific binding peptide and screening method thereof |
| CN102586193A (en) * | 2012-02-10 | 2012-07-18 | 中国农业科学院上海兽医研究所 | Monoclonal antibody for resisting duck tembusu virus, hybridoma strain and application thereof |
-
2014
- 2014-07-25 CN CN201410361045.1A patent/CN104193804B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101412750A (en) * | 2008-10-08 | 2009-04-22 | 南京农业大学 | Bursin specific binding peptide and screening method thereof |
| CN102586193A (en) * | 2012-02-10 | 2012-07-18 | 中国农业科学院上海兽医研究所 | Monoclonal antibody for resisting duck tembusu virus, hybridoma strain and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| XIAOFEI BAI ET AL.: "Molecular characterization of a duck Tembusu virus from China", 《VIRUS GENES》 * |
| 李振华等: "鸭坦布苏病毒灭活油乳苗的制备及免疫效力测定", 《中国预防兽医学报》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109865138A (en) * | 2017-12-05 | 2019-06-11 | 江苏省农业科学院 | A kind of application of tembusu virus E protein receptor binding domains |
| CN109865138B (en) * | 2017-12-05 | 2022-03-22 | 江苏省农业科学院 | Application of tembusu virus E protein receptor binding domain |
| CN114315991A (en) * | 2020-10-30 | 2022-04-12 | 广西壮族自治区动物疫病预防控制中心 | Competitive ELISA method based on duck flavivirus E protein and monoclonal antibody thereof |
| CN114315991B (en) * | 2020-10-30 | 2024-06-11 | 广西壮族自治区动物疫病预防控制中心 | Duck flavivirus E protein and monoclonal antibody-based competition ELISA method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104193804B (en) | 2016-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104193805A (en) | Duck tembusu virus envelop E protein inhibitory peptide and application thereof | |
| CN107245095B (en) | Polypeptide inhibitor for inhibiting ten kinds of coronavirus | |
| CN107619819A (en) | A kind of recombinant cell lines, vaccine and the application of stable expression Porcine epidemic diarrhea virus S1 albumen | |
| CN101724605B (en) | Foot-and-mouth disease virus (FMDV) resistant monoclonal antibody and identified epitope and application thereof | |
| CN104193804A (en) | Specific binding peptide of duck tembusu virus envelope E protein and application thereof | |
| CN103694321A (en) | Staphylococcus aureus mSEB mutant and preparation method and application thereof | |
| CN102058881B (en) | Gene recombinant vaccine for preventing enterovirus 71 infection and preparation method thereof | |
| CN101948510B (en) | Molecular mimic peptide of type O foot and mouth disease virus VP2 epitope and applications thereof | |
| Xiong et al. | Antigenic identification of virion structural proteins from infectious spleen and kidney necrosis virus | |
| CN109776657A (en) | Recombinate norovirus VLP particle and preparation method and its usage | |
| CN103013929B (en) | Avian influenza virus, and detection kit and vaccine thereof | |
| CN105037499B (en) | It is directed to people's histamine receptor 4 using phage antibody library（HR4）Epitope mimic peptide screening and its vaccine construction method | |
| CN104193803A (en) | Duck hepatitis virus (DHV) I type VP1 protein inhibitory peptide and application thereof | |
| CN101948546B (en) | Fusion protein SAmB as well as coding gene and applications thereof | |
| CN108395470B (en) | Short peptide with dengue virus replication inhibition effect and application thereof | |
| CN110845584A (en) | Hog cholera virus envelope protein oligomeric protein body and preparation method and application thereof | |
| CN104774249B (en) | Porcine epidemic diarrhea virus M albumen affinity peptide and its screening technique | |
| CN101186644B (en) | H3 type flu virus hemagglutinin space conformation simulation antigen epitope and application thereof | |
| Xu et al. | A novel linear epitope at the C-terminal region of the classical swine fever virus E2 protein elicits neutralizing activity | |
| CN106928327B (en) | Hog cholera virus ligand epitope polypeptide SE242 and application thereof | |
| CN104163854A (en) | Duck hepatitis virus type I VP1 protein specific binding peptide and application | |
| CN101798337B (en) | Mutant of endotoxin neutralizing peptide and application thereof | |
| CN104788572B (en) | For detecting PCV2 fusion protein, preparation method and application | |
| CN104130313B (en) | Synthetic bursin BPP-II specific binding peptides and application thereof | |
| CN102382171B (en) | Polypeptide for inhibiting hepatitis C virus infected cell and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160824 Termination date: 20170725 |